Onco-Innovations Advances Next-Gen Cancer Therapy With PNKP Inhibitor & AI Partnership

3 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Onco-Innovations CEO Thomas O’Shaughnessy joined Steve Darling from Proactive to discuss the company’s cutting-edge approach to cancer treatment in response to the projected 47-48% rise in global cancer cases by 2040. The company is pioneering next-generation therapies based on precision medicine and nanotechnology, with an initial focus on solid tumors, particularly colorectal cancer.

O’Shaughnessy highlighted that Onco-Innovations’ patented drug formulation and nanoparticle technology are designed to enhance chemotherapy and radiation by making cancer cells more susceptible to treatment. Central to its innovation is a licensed PNKP inhibitor, a new class of drug that blocks cancer cells from repairing DNA damage, making existing therapies more effective. Additionally, the company is leveraging nanoparticle delivery systems to improve drug targeting and efficiency.

Further strengthening its position in precision oncology, Onco-Innovations recently signed a Letter of Intent (LOI) with Inka Health AI, a company specializing in AI-driven oncology diagnostics. This partnership aims to enhance personalized cancer treatment strategies by integrating patient-specific data into therapy development.

O’Shaughnessy expressed excitement about Onco-Innovations’ growth following its IPO, emphasizing the company’s commitment to transforming cancer care through cutting-edge research and strategic collaborations.

#proactiveinvestors #once-innovationslimited #cse #onco #CancerTreatment #PrecisionMedicine #Biotech #Oncology #CancerResearch #Pharma #Healthcare #MedicalBreakthrough #AIinMedicine
Category
Oncology
Be the first to comment

Up Next